The potential to treat HBV
DCR-HBVS is in development for the treatment of chronic hepatitis B virus (HBV) infection in adults. Hepatitis B is a serious liver infection. Chronic hepatitis B increases the risk of developing liver failure, liver cancer or cirrhosis — a condition that permanently scars the liver. Current therapies typically provide long-term suppression of the virus, but DCR-HBVS has the potential to provide a functional cure for patients with chronic HBV.
DCR-HBVS leverages the power of RNAi to target the messenger RNA (mRNA) of HBV. We measure the ability for a drug to provide a long-term functional cure of HBV through the clearance of HBV surface antigen (HBsAg) and sustained HBV deoxyribonucleic acid (DNA) suppression in patient plasma or blood.
In mouse models of HBV infection, DCR-HBVS leads to greater than 99.9% reduction in circulating HBsAg, suggesting that the compound may induce long-term clearance of HBsAg. With its long-acting mechanism, DCR-HBVS may help harness the body’s own immune system to help individuals with chronic HBV infection achieve a functional cure.
DCR-HBVS phase 1 clinical trial
In October 2019, we entered into a research and licensing agreement with Roche to develop DCR-HBVS for the treatment of patients with non-cirrhotic chronic HBV. We are evaluating DCR-HBVS in the DCR-HBVS Phase 1 clinical trial. This Phase 1 clinical trial of DCR-HBVS is a randomized, placebo-controlled study designed to evaluate the safety and tolerability of DCR-HBVS in healthy volunteers and in patients with non-cirrhotic chronic HBV.
- Mayo Clinic. Hepatitis B. Rochester, MN.: Mayo Foundation for Medical Education and Research (MFMER); 2019. Available at: https://www.mayoclinic.org/diseases-conditions/hepatitis-b/symptoms-causes/syc-20366802. Accessed Dec. 30, 2019.